Bristol-Myers Squibb Company PFD CONV 2
BMYMP · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $48,300,000 | $45,006,000 | $46,159,000 | $46,385,000 |
| % Growth | 7.3% | -2.5% | -0.5% | – |
| Cost of Goods Sold | $20,868,000 | $19,649,000 | $19,669,000 | $19,624,000 |
| Gross Profit | $27,432,000 | $25,357,000 | $26,490,000 | $26,761,000 |
| % Margin | 56.8% | 56.3% | 57.4% | 57.7% |
| R&D Expenses | $9,782,000 | $9,207,000 | $9,411,000 | $9,533,000 |
| G&A Expenses | $6,365,000 | $0 | $0 | $0 |
| SG&A Expenses | $7,865,000 | $7,678,000 | $7,808,000 | $7,688,000 |
| Sales & Mktg Exp. | $1,500,000 | $0 | $0 | $0 |
| Other Operating Expenses | $127,000 | $0 | $0 | $0 |
| Operating Expenses | $17,774,000 | $16,885,000 | $17,219,000 | $17,221,000 |
| Operating Income | $9,658,000 | $8,472,000 | $9,271,000 | $9,540,000 |
| % Margin | 20% | 18.8% | 20.1% | 20.6% |
| Other Income/Exp. Net | -$18,037,000 | -$32,000 | -$1,558,000 | -$1,442,000 |
| Pre-Tax Income | -$8,379,000 | $8,440,000 | $7,713,000 | $8,098,000 |
| Tax Expense | $554,000 | $400,000 | $1,368,000 | $1,084,000 |
| Net Income | -$8,948,000 | $8,025,000 | $6,327,000 | $6,994,000 |
| % Margin | -18.5% | 17.8% | 13.7% | 15.1% |
| EPS | -4.41 | 3.88 | 2.97 | 3.15 |
| % Growth | -213.7% | 30.6% | -5.7% | – |
| EPS Diluted | -4.41 | 3.86 | 2.95 | 3.12 |
| Weighted Avg Shares Out | 2,027,000 | 2,069,000 | 2,130,000 | 2,221,000 |
| Weighted Avg Shares Out Dil | 2,027,000 | 2,078,000 | 2,146,000 | 2,245,000 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1,947,000 | $1,166,000 | $1,232,000 | $1,334,000 |
| Depreciation & Amortization | $9,600,000 | $9,760,000 | $10,276,000 | $10,686,000 |
| EBITDA | $3,168,000 | $19,366,000 | $19,221,000 | $20,118,000 |
| % Margin | 6.6% | 43% | 41.6% | 43.4% |